Ivan H. El-Sayed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ivan H. El-Sayed has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Patrick K. Ha
Department of Otolaryngology‐Head and Neck Surgery University of California San Francisco California USA
12 shared publications Jonathan R. George
Department of Otolaryngology‐Head and Neck Surgery University of California San Francisco California USA
11 shared publications- Katherine C. Wai
Department of Otolaryngology‐Head and Neck Surgery University of California San Francisco California USA
11 shared publications - Chase M. Heaton
Department of Otolaryngology‐Head and Neck Surgery University of California San Francisco California USA
9 shared publications Ilya Likhterov
Department of Otolaryngology‐Head and Neck Surgery University of California San Francisco California USA
8 shared publications- Rex Hayden Lee
Department of Otolaryngology‐Head and Neck Surgery University of California San Francisco California USA
8 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study
Background: Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with high recurrence rates and limited prospective data to guide postoperative management. While immune checkpoint inhibitors (ICI) have reshaped melanoma treatment, their survival impact in resected HNMM remains poorly defined. We evaluated real‐world outcomes after curative‐intent surgery and the association of adjuvant immune checkpoint inhibitor (ICI) therapy with survival. Methods: We retrospectively identified patients with HNMM who underwent curative‐intent surgery from 1990 to 2024. Overall survival (OS) and progression‐free survival (PFS) were estimated from surgery using Kaplan–Meier methods. Univariable Cox models evaluated associations of adjuvant ICI with survival. Results: Among 89 patients, median follow‐up was 38 months (IQR, 18–60). Most tumors arose in the nasal cavity or paranasal sinuses (72/89, 81%); 23 (26%) had T4 disease and 7 (8%) had regional nodal metastases. Among tested patients, BRAF, NRAS, and KIT alterations were identified in 4/37 (11%), 7/25 (28%), and 0/28 (0%), respectively. Median tumor mutational burden was 3.45 mutations/Mb (IQR, 2.15–7.95; n = 10) and median PD‐L1 tumor proportion score was 0.5% (IQR, 0%–1%; n = 6). Seventeen patients (19%) received adjuvant ICI, including anti–PD‐1 monotherapy ( n = 10), CTLA‐4 monotherapy ( n = 1), or combination anti–PD‐1/CTLA‐4 therapy ( n = 6); 48 (54%) received adjuvant radiotherapy. Two‐ and 5‐year OS were 66% and 46%, respectively; corresponding PFS estimates were 65% and 46%. Adjuvant ICI was not associated with improved OS (hazard ratio [HR], 0.69; 95% CI, 0.31–1.55; p = 0.37) or PFS (HR, 1.06; 95% CI, 0.50–2.21; p = 0.88). Initial progression patterns were broadly similar between groups. Conclusions: In this single‐institution cohort of surgically treated HNMM, adjuvant ICI was not associated with improved OS or PFS. Patterns of initial disease progression were similar between treatment groups, underscoring the need for more effective peri‐operative strategies.
- 11 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessAdjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study
Background: Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with high recurrence rates and limited prospective data to guide postoperative management. While immune checkpoint inhibitors (ICI) have reshaped melanoma treatment, their survival impact in resected HNMM remains poorly defined. We evaluated real‐world outcomes after curative‐intent surgery and the association of adjuvant immune checkpoint inhibitor (ICI) therapy with survival. Methods: We retrospectively identified patients with HNMM who underwent curative‐intent surgery from 1990 to 2024. Overall survival (OS) and progression‐free survival (PFS) were estimated from surgery using Kaplan–Meier methods. Univariable Cox models evaluated associations of adjuvant ICI with survival. Results: Among 89 patients, median follow‐up was 38 months (IQR, 18–60). Most tumors arose in the nasal cavity or paranasal sinuses (72/89, 81%); 23 (26%) had T4 disease and 7 (8%) had regional nodal metastases. Among tested patients, BRAF, NRAS, and KIT alterations were identified in 4/37 (11%), 7/25 (28%), and 0/28 (0%), respectively. Median tumor mutational burden was 3.45 mutations/Mb (IQR, 2.15–7.95; n = 10) and median PD‐L1 tumor proportion score was 0.5% (IQR, 0%–1%; n = 6). Seventeen patients (19%) received adjuvant ICI, including anti–PD‐1 monotherapy ( n = 10), CTLA‐4 monotherapy ( n = 1), or combination anti–PD‐1/CTLA‐4 therapy ( n = 6); 48 (54%) received adjuvant radiotherapy. Two‐ and 5‐year OS were 66% and 46%, respectively; corresponding PFS estimates were 65% and 46%. Adjuvant ICI was not associated with improved OS (hazard ratio [HR], 0.69; 95% CI, 0.31–1.55; p = 0.37) or PFS (HR, 1.06; 95% CI, 0.50–2.21; p = 0.88). Initial progression patterns were broadly similar between groups. Conclusions: In this single‐institution cohort of surgically treated HNMM, adjuvant ICI was not associated with improved OS or PFS. Patterns of initial disease progression were similar between treatment groups, underscoring the need for more effective peri‐operative strategies.
- Open Access
- 21 October 2026
- Published by Wiley in Head & Neck
Obesity and Pathologic Response to Neoadjuvant Immunotherapy in Head and Neck Cancer: Preliminary Results From a Pilot Study
Objective: To evaluate associations between obesity and pathologic response to neoadjuvant immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC). Methods: This was a retrospective cohort study conducted at a single tertiary academic center. We identified 42 patients with HNSCC treated with neoadjuvant ICI with or without chemotherapy. Obesity was defined as body mass index (BMI) ≥ 30 kg/m 2 . The primary outcome was any pathologic response (partial, major, or complete response). Multivariable logistic regression was performed to assess associations between obesity and response, adjusting for smoking status and Eastern Cooperative Oncology Group (ECOG) performance status. BMI was also analyzed as a continuous variable. Adjusted predicted probabilities of response were estimated across BMI. Results: Seven patients (17%) were obese. Obese patients had lower rates of pathologic response compared to non‐obese patients (29% vs. 69%). On multivariable analysis, obesity was associated with decreased odds of response (OR 0.10, 95% CI 0.02–0.72; p = 0.021). Increasing BMI was independently associated with lower odds of response, with a 15% decrease per 1 kg/m 2 increase [OR 0.85 (0.72–0.99), p = 0.039]. Adjusted predicted probability of response declined from ~85% at BMI 18 to 25% at BMI 40. In a subset of patients receiving immunotherapy alone, increasing BMI remained associated with decreased response [OR 0.66 (0.44–0.99), p = 0.045]. Conclusion: In a small pilot cohort, obesity was associated with decreased pathologic response to neoadjuvant ICI in HNSCC. These findings contrast with the “obesity paradox” observed in recurrent/metastatic settings and suggest the relationship between metabolic state and immunotherapy response may be context‐dependent. Further validation in larger cohorts is needed. Level of Evidence: III.
- 21 October 2026
- Published by Wiley in Head & Neck
Open AccessObesity and Pathologic Response to Neoadjuvant Immunotherapy in Head and Neck Cancer: Preliminary Results From a Pilot Study
Objective: To evaluate associations between obesity and pathologic response to neoadjuvant immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC). Methods: This was a retrospective cohort study conducted at a single tertiary academic center. We identified 42 patients with HNSCC treated with neoadjuvant ICI with or without chemotherapy. Obesity was defined as body mass index (BMI) ≥ 30 kg/m 2 . The primary outcome was any pathologic response (partial, major, or complete response). Multivariable logistic regression was performed to assess associations between obesity and response, adjusting for smoking status and Eastern Cooperative Oncology Group (ECOG) performance status. BMI was also analyzed as a continuous variable. Adjusted predicted probabilities of response were estimated across BMI. Results: Seven patients (17%) were obese. Obese patients had lower rates of pathologic response compared to non‐obese patients (29% vs. 69%). On multivariable analysis, obesity was associated with decreased odds of response (OR 0.10, 95% CI 0.02–0.72; p = 0.021). Increasing BMI was independently associated with lower odds of response, with a 15% decrease per 1 kg/m 2 increase [OR 0.85 (0.72–0.99), p = 0.039]. Adjusted predicted probability of response declined from ~85% at BMI 18 to 25% at BMI 40. In a subset of patients receiving immunotherapy alone, increasing BMI remained associated with decreased response [OR 0.66 (0.44–0.99), p = 0.045]. Conclusion: In a small pilot cohort, obesity was associated with decreased pathologic response to neoadjuvant ICI in HNSCC. These findings contrast with the “obesity paradox” observed in recurrent/metastatic settings and suggest the relationship between metabolic state and immunotherapy response may be context‐dependent. Further validation in larger cohorts is needed. Level of Evidence: III.
- 8 September 2026
- Published by Wiley in Head & Neck
Statin Use Is Associated With Progression‐Free Survival for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab
Background: Statins may modulate immune function and enhance immunotherapy response. This study evaluated the relationship between statin use and outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving pembrolizumab. Methods: A retrospective observational study was conducted at UCSF including patients with oral cavity, oropharyngeal, hypopharyngeal, laryngeal, or cutaneous HNSCC treated with pembrolizumab from 2016 to 2022. Primary outcome was 6‐month progression‐free survival (PFS); secondary was 2‐year overall survival (OS). Results: Among 165 patients, 60 (36%) used statins. After adjustment for ECOG status, concurrent systemic therapy, and tumor site, any statin use (HR 0.49, p = 0.012), high‐intensity statins (HR 0.46, p = 0.012), and lipophilic statin use (HR 0.54, p = 0.041) were associated with improved 6‐month PFS. Conclusions: Statin use, particularly high‐intensity regimens, was associated with improved short‐term outcomes on pembrolizumab in HNSCC. Prospective studies are warranted to elucidate underlying mechanisms.
- 8 September 2026
- Published by Wiley in Head & Neck
Statin Use Is Associated With Progression‐Free Survival for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab
Background: Statins may modulate immune function and enhance immunotherapy response. This study evaluated the relationship between statin use and outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving pembrolizumab. Methods: A retrospective observational study was conducted at UCSF including patients with oral cavity, oropharyngeal, hypopharyngeal, laryngeal, or cutaneous HNSCC treated with pembrolizumab from 2016 to 2022. Primary outcome was 6‐month progression‐free survival (PFS); secondary was 2‐year overall survival (OS). Results: Among 165 patients, 60 (36%) used statins. After adjustment for ECOG status, concurrent systemic therapy, and tumor site, any statin use (HR 0.49, p = 0.012), high‐intensity statins (HR 0.46, p = 0.012), and lipophilic statin use (HR 0.54, p = 0.041) were associated with improved 6‐month PFS. Conclusions: Statin use, particularly high‐intensity regimens, was associated with improved short‐term outcomes on pembrolizumab in HNSCC. Prospective studies are warranted to elucidate underlying mechanisms.
- Open Access
- 4 September 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (5) , e70117
A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines
Mucosal and acral melanomas are rare subtypes of melanoma with unique clinical and biological features. A dearth of well‐established and characterized melanoma cell lines that reflect rare subtypes impedes research on these lethal diseases. We present a protocol developed by exploring various combinations of established techniques that we used to generate mucosal and acral cell lines from patient tissues and patient derived xenografts.
- 4 September 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (5) , e70117
Open AccessA Technique for the Generation of Mucosal and Acral Melanoma Cell Lines
Mucosal and acral melanomas are rare subtypes of melanoma with unique clinical and biological features. A dearth of well‐established and characterized melanoma cell lines that reflect rare subtypes impedes research on these lethal diseases. We present a protocol developed by exploring various combinations of established techniques that we used to generate mucosal and acral cell lines from patient tissues and patient derived xenografts.
- 18 June 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3329-3336
Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab
Background: The prognostic implications of regional lymph node metastases at the initiation of immune checkpoint inhibitor (ICI) therapy in oral cavity squamous cell carcinoma (OCSCC) are not well defined. This study evaluated whether the presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with progression‐free or overall survival among patients with recurrent or metastatic (R/M) OCSCC. Methods: A retrospective cohort study was conducted at a tertiary academic medical center including patients with R/M OCSCC who initiated pembrolizumab between May 2016 and May 2022. Patients receiving fewer than three cycles were excluded. The presence of metastatic lymph node(s) at ICI initiation was analyzed as a dichotomous variable. The primary outcome was 6‐month progression‐free survival (PFS), and the secondary outcome was 2‐year overall survival (OS). Disease progression was determined using RECIST‐based radiographic criteria. Cox proportional hazards models adjusted for age, PD‐L1 status, presence of distant metastases, and receipt of concurrent systemic therapy. Results: Forty‐five patients met inclusion criteria; all received pembrolizumab for R/M disease. Twelve patients (27%) had metastatic cervical lymph nodes at ICI initiation. On univariate analysis, nodal metastasis was associated with poorer 6‐month PFS ( p = 0.024). After adjustment for age, PD‐L1 status, distant metastases, and concurrent systemic therapy, cervical nodal metastasis remained independently associated with inferior PFS (HR 5.12; 95% CI 1.30–20.2; p = 0.020). Conclusions: Presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with reduced 6‐month progression‐free survival, suggesting regional disease burden may predict limited ICI benefit in R/M OCSCC.
- 18 June 2026
- Published by Wiley in Head & Neck
- Vol. 48 (12) , 3329-3336
Metastatic Lymph Node Status Is Associated With Progression‐Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab
Background: The prognostic implications of regional lymph node metastases at the initiation of immune checkpoint inhibitor (ICI) therapy in oral cavity squamous cell carcinoma (OCSCC) are not well defined. This study evaluated whether the presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with progression‐free or overall survival among patients with recurrent or metastatic (R/M) OCSCC. Methods: A retrospective cohort study was conducted at a tertiary academic medical center including patients with R/M OCSCC who initiated pembrolizumab between May 2016 and May 2022. Patients receiving fewer than three cycles were excluded. The presence of metastatic lymph node(s) at ICI initiation was analyzed as a dichotomous variable. The primary outcome was 6‐month progression‐free survival (PFS), and the secondary outcome was 2‐year overall survival (OS). Disease progression was determined using RECIST‐based radiographic criteria. Cox proportional hazards models adjusted for age, PD‐L1 status, presence of distant metastases, and receipt of concurrent systemic therapy. Results: Forty‐five patients met inclusion criteria; all received pembrolizumab for R/M disease. Twelve patients (27%) had metastatic cervical lymph nodes at ICI initiation. On univariate analysis, nodal metastasis was associated with poorer 6‐month PFS ( p = 0.024). After adjustment for age, PD‐L1 status, distant metastases, and concurrent systemic therapy, cervical nodal metastasis remained independently associated with inferior PFS (HR 5.12; 95% CI 1.30–20.2; p = 0.020). Conclusions: Presence of metastatic cervical lymph nodes at the start of pembrolizumab therapy was associated with reduced 6‐month progression‐free survival, suggesting regional disease burden may predict limited ICI benefit in R/M OCSCC.
- 14 May 2026
- Published by Wiley in Head & Neck
- Vol. 48 (11) , 3016-3022
Changes in Time to Diagnosis of HPV + Oropharyngeal Squamous Cell Carcinoma
Background: Timely referral to subspecialty care remains critical for expedited work up and treatment of HPV + oropharyngeal carcinoma (OPSCC). It is not known if there have been changes in time to diagnosis as the incidence of this disease rises. Methods: Retrospective cohort study of 312 patients treated for HPV + OPSCC at a tertiary referral clinic between 2013 and 2022. Results: There was a significant difference in time to diagnosis based on year of presentation ( p < 0.001). More patients presented with early‐stage disease (AJCC 7 Stage I or II) over time ( p = 0.002). Presenting symptom ( p = 0.021) and patient location ≥ 50 miles from our tertiary referral clinic ( p = 0.039) also affected time to diagnosis. Conclusions: Time to diagnosis of HPV + OPSCC changed based on year of presentation, and a higher proportion of patients presented with early‐stage disease in more recent years. This may reflect an increased public awareness of HPV + OPSCC and its symptoms.
- 14 May 2026
- Published by Wiley in Head & Neck
- Vol. 48 (11) , 3016-3022
Changes in Time to Diagnosis of HPV + Oropharyngeal Squamous Cell Carcinoma
Background: Timely referral to subspecialty care remains critical for expedited work up and treatment of HPV + oropharyngeal carcinoma (OPSCC). It is not known if there have been changes in time to diagnosis as the incidence of this disease rises. Methods: Retrospective cohort study of 312 patients treated for HPV + OPSCC at a tertiary referral clinic between 2013 and 2022. Results: There was a significant difference in time to diagnosis based on year of presentation ( p < 0.001). More patients presented with early‐stage disease (AJCC 7 Stage I or II) over time ( p = 0.002). Presenting symptom ( p = 0.021) and patient location ≥ 50 miles from our tertiary referral clinic ( p = 0.039) also affected time to diagnosis. Conclusions: Time to diagnosis of HPV + OPSCC changed based on year of presentation, and a higher proportion of patients presented with early‐stage disease in more recent years. This may reflect an increased public awareness of HPV + OPSCC and its symptoms.
- Open Access
- 12 May 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (3)
Optimizing Skull Base Anatomy Education: Qualitative Insights From Learner Interaction With 2D , Monoscopic 3D , and Virtual Reality Models
Objective: Several models are currently employed to teach anatomy to medical students and residents, including cadaveric, two‐dimensional (2D), monoscopic three‐dimensional (3D), and virtual reality (VR) models. While many studies have focused on measuring how much and how quickly each model can help residents and medical students attain and remember anatomical facts, few studies have compared how models might help learners achieve other aspects of learning (such as synthesis of facts). We sought to investigate how residents and faculty interact with 2D, 3D, and VR models as learning tools for complex head and neck anatomy to improve and inform the design of learning modalities of head and neck anatomy for otolaryngology residents. Methods: A convenience sample of faculty and residents in the otolaryngology and neurosurgical departments was invited to complete semi‐structured interviews regarding their perceptions of learning models in different dimensions. 2D, 3D, and VR models of infratemporal fossa (ITF) anatomy were created from the same cadaveric head using photogrammetry. Semi‐structured interviews were performed as participants moved through three stations (2D, 3D, and VR), exploring participant perceptions and how they would use each model to assess affordances and barriers to improve and inform design of these learning models. Three investigators analyzed the transcripts using thematic content analysis. Results: Eleven interviews were conducted (four attendings and seven residents). Four themes arose related to perceptions and barriers of the learning models: 2D is preferred for learning head and neck anatomy for the first time; 3D and VR are preferred for self‐driven discovery for affording deeper understanding of and for reviewing anatomy; models that prepare participants for the operation room are more preferable; and current models do not adequately balance clarity versus comprehensiveness. Conclusions: These findings help inform design principles for anatomical models tailored to resident level of training. Level of Evidence: N/A
- 12 May 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (3)
Open AccessOptimizing Skull Base Anatomy Education: Qualitative Insights From Learner Interaction With 2D , Monoscopic 3D , and Virtual Reality Models
Objective: Several models are currently employed to teach anatomy to medical students and residents, including cadaveric, two‐dimensional (2D), monoscopic three‐dimensional (3D), and virtual reality (VR) models. While many studies have focused on measuring how much and how quickly each model can help residents and medical students attain and remember anatomical facts, few studies have compared how models might help learners achieve other aspects of learning (such as synthesis of facts). We sought to investigate how residents and faculty interact with 2D, 3D, and VR models as learning tools for complex head and neck anatomy to improve and inform the design of learning modalities of head and neck anatomy for otolaryngology residents. Methods: A convenience sample of faculty and residents in the otolaryngology and neurosurgical departments was invited to complete semi‐structured interviews regarding their perceptions of learning models in different dimensions. 2D, 3D, and VR models of infratemporal fossa (ITF) anatomy were created from the same cadaveric head using photogrammetry. Semi‐structured interviews were performed as participants moved through three stations (2D, 3D, and VR), exploring participant perceptions and how they would use each model to assess affordances and barriers to improve and inform design of these learning models. Three investigators analyzed the transcripts using thematic content analysis. Results: Eleven interviews were conducted (four attendings and seven residents). Four themes arose related to perceptions and barriers of the learning models: 2D is preferred for learning head and neck anatomy for the first time; 3D and VR are preferred for self‐driven discovery for affording deeper understanding of and for reviewing anatomy; models that prepare participants for the operation room are more preferable; and current models do not adequately balance clarity versus comprehensiveness. Conclusions: These findings help inform design principles for anatomical models tailored to resident level of training. Level of Evidence: N/A
- 10 May 2026
- Published by Wiley in Head & Neck
- Vol. 48 (10) , 2863-2870
Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer
Background: A minority of patients receiving immunotherapy for oropharyngeal head and neck squamous cell carcinoma benefit. Finding biomarkers that predict response to ICI is important for improving outcomes in these patients. In this study, we determine the relationship between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) oropharyngeal cancer on pembrolizumab. Methods: This study was a retrospective cohort study of patients with recurrent/metastatic OPSCC who were treated with pembrolizumab between May 2016 and May 2022 at a tertiary care academic center. The primary outcome was 6‐month progression‐free survival. The secondary outcome was 2‐year overall survival. NLR was treated as a continuous and dichotomous variable. Disease progression was determined using radiographic criteria adopted from the Response Evaluation Criteria in Solid Tumors. Results: Sixty‐four patients with OPSCC were included. The median pre‐treatment NLR was 5.1 (IQR 3.1–8.3). Thirty‐seven (58%) patients had distant metastases at the start of ICI. When treated as a continuous variable, higher pretreatment NLR was associated with poorer 6‐month PFS [HR 1.14 (1.03, 1.27), p = 0.016] and 2‐year OS [HR 1.21 (1.09, 1.35), p = 0.001] for patients on pembrolizumab. Subgroup analyzes on patients who were p16+ versus p16‐ revealed that NLR was only associated with poorer survival for p16+ patients [HR 1.16 (1.00, 1.33), p = 0.046 versus HR 1.11 (0.94, 1.31), p = 0.203, respectively]. Conclusion: Higher pretreatment NLR was associated with poorer 6‐month PFS and 2‐year OS in OPSCC patients treated with pembrolizumab. When stratified by p16 status, this association only remained significant among p16+ patients.
- 10 May 2026
- Published by Wiley in Head & Neck
- Vol. 48 (10) , 2863-2870
Neutrophil‐To‐Lymphocyte Ratio and Survival in Pembrolizumab‐Treated Oropharyngeal Cancer
Background: A minority of patients receiving immunotherapy for oropharyngeal head and neck squamous cell carcinoma benefit. Finding biomarkers that predict response to ICI is important for improving outcomes in these patients. In this study, we determine the relationship between pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and 6‐month progression‐free survival (PFS)/2‐year overall survival (OS) among patients with recurrent or metastatic (R/M) oropharyngeal cancer on pembrolizumab. Methods: This study was a retrospective cohort study of patients with recurrent/metastatic OPSCC who were treated with pembrolizumab between May 2016 and May 2022 at a tertiary care academic center. The primary outcome was 6‐month progression‐free survival. The secondary outcome was 2‐year overall survival. NLR was treated as a continuous and dichotomous variable. Disease progression was determined using radiographic criteria adopted from the Response Evaluation Criteria in Solid Tumors. Results: Sixty‐four patients with OPSCC were included. The median pre‐treatment NLR was 5.1 (IQR 3.1–8.3). Thirty‐seven (58%) patients had distant metastases at the start of ICI. When treated as a continuous variable, higher pretreatment NLR was associated with poorer 6‐month PFS [HR 1.14 (1.03, 1.27), p = 0.016] and 2‐year OS [HR 1.21 (1.09, 1.35), p = 0.001] for patients on pembrolizumab. Subgroup analyzes on patients who were p16+ versus p16‐ revealed that NLR was only associated with poorer survival for p16+ patients [HR 1.16 (1.00, 1.33), p = 0.046 versus HR 1.11 (0.94, 1.31), p = 0.203, respectively]. Conclusion: Higher pretreatment NLR was associated with poorer 6‐month PFS and 2‐year OS in OPSCC patients treated with pembrolizumab. When stratified by p16 status, this association only remained significant among p16+ patients.
- Open Access
- 27 February 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (2) , e70363
Timely Matters: Predictors of Delay in Oral Cavity Cancer Patients Across the Care Continuum
Objective: Limited literature focuses on delays in accessing head and neck cancer (HNC) care across the entire care continuum. This study aims to describe the time to care from symptom onset to treatment completion and identify predictors of delays for oral cavity cancer patients. Methods: We reviewed patients with oral cavity squamous cell carcinoma (OCSCC) treated with curative surgery followed by adjuvant treatment at a tertiary center. Delays were defined per published thresholds for: time to treatment initiation (TTI, diagnosis to surgery), time to adjuvant treatment (stratified by whether adjuvant treatment was at the same or different facility as surgery), and total treatment package time. We also measured symptom duration, reported median times, and used logistic regression to assess predictors of delay. Results: Among 93 patients, median (IQR) symptom duration was 17.4 weeks (IQR: 6.8–42.8); TTI 6.9 weeks (IQR: 4.4–10.4); time to adjuvant radiation 8.4 weeks (IQR: 7.4–9.3) at the same institution as surgery was performed and 9.3 weeks (IQR: 7.4–14) at a different facility; and total treatment package time 15.4 weeks (IQR: 12.6–20) for surgery and adjuvant radiation, and 16.3 weeks (IQR: 15–18.6) for surgery and adjuvant chemoradiation. 73% of patients experienced delays in reaching a healthcare facility, 39% in TTI, 89% in starting adjuvant treatment, and 64%–81% in total treatment time. In univariate analyses, late‐stage disease, residing in a community with higher social vulnerability index (SVI), longer time from surgery to pathology report, need for free flap, and social worker interaction were associated with higher odds of delay in any care interval following diagnosis. Higher SVI was associated with delays in multivariate analyses. Conclusion: HNC patients experience delays during all phases of cancer care. Interventions and future research need to address social determinants of health and health system factors that contribute to multifactorial delays across the care continuum.
- 27 February 2026
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (2) , e70363
Open AccessTimely Matters: Predictors of Delay in Oral Cavity Cancer Patients Across the Care Continuum
Objective: Limited literature focuses on delays in accessing head and neck cancer (HNC) care across the entire care continuum. This study aims to describe the time to care from symptom onset to treatment completion and identify predictors of delays for oral cavity cancer patients. Methods: We reviewed patients with oral cavity squamous cell carcinoma (OCSCC) treated with curative surgery followed by adjuvant treatment at a tertiary center. Delays were defined per published thresholds for: time to treatment initiation (TTI, diagnosis to surgery), time to adjuvant treatment (stratified by whether adjuvant treatment was at the same or different facility as surgery), and total treatment package time. We also measured symptom duration, reported median times, and used logistic regression to assess predictors of delay. Results: Among 93 patients, median (IQR) symptom duration was 17.4 weeks (IQR: 6.8–42.8); TTI 6.9 weeks (IQR: 4.4–10.4); time to adjuvant radiation 8.4 weeks (IQR: 7.4–9.3) at the same institution as surgery was performed and 9.3 weeks (IQR: 7.4–14) at a different facility; and total treatment package time 15.4 weeks (IQR: 12.6–20) for surgery and adjuvant radiation, and 16.3 weeks (IQR: 15–18.6) for surgery and adjuvant chemoradiation. 73% of patients experienced delays in reaching a healthcare facility, 39% in TTI, 89% in starting adjuvant treatment, and 64%–81% in total treatment time. In univariate analyses, late‐stage disease, residing in a community with higher social vulnerability index (SVI), longer time from surgery to pathology report, need for free flap, and social worker interaction were associated with higher odds of delay in any care interval following diagnosis. Higher SVI was associated with delays in multivariate analyses. Conclusion: HNC patients experience delays during all phases of cancer care. Interventions and future research need to address social determinants of health and health system factors that contribute to multifactorial delays across the care continuum.